Xeris Biopharma Holdings, Inc. announced the expansion of the Company's Board of Directors (the "Board") from 8 to 9 members and the appointment of Ricki Fairley to the Board on March 27, 2023. Ms. Fairley will serve as a Class III director whose term will expire at the Company's 2024 annual meeting of shareholders, or until her successor is duly elected and qualified. Ms. Fairley has not been appointed to any committee of the Board at this time.

Ms. Fairley has over 35 years of marketing experience including 20 years in brand management at Johnson & Johnson, Nabisco, Reckitt & Colman, and The Coca-Cola Company, and over 15 years in agency leadership encompassing strategic planning and consulting for numerous Fortune 500 companies. She currently serves as co-founder and CEO of TOUCH, The Black Breast Cancer Alliance. Ms. Fairley holds a BA from Dartmouth College and an MBA from Kellogg School of Management at Northwestern University.

There are no arrangements or understandings between Ms. Fairley and any other person pursuant to which Ms. Fairley was appointed to the Board. There are no family relationships between Ms. Fairley and any of the Company's directors or other executive officers, and Ms. Fairley is not a party to any transaction, or any proposed transaction, required to be disclosed pursuant to Item 404(a) of regulation S-K.